HNRNPA2B1 and hepatocellular carcinoma: Although high HNRNPA2B1 expression is generally associated with poorer prognosis in HCC, it paradoxically correlated with longer overall survival in the IMvigor210 cohort receiving anti-PD-L1 therapy (P=0.047)231.